VASCULITIS SYNDROMES: Edited by Hasan Yazici and Yusuf YaziciManagement of Behçet's syndromeOzguler, Yesim; Hatemi, GulenAuthor Information Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey Correspondence to Gulen Hatemi, Cerrahpasa Tip Fakultesi, Ic Hastaliklari ABD, Aksaray, Istanbul, Turkey. Tel: +90212 4143000; fax: +90212 5890808; e-mail: firstname.lastname@example.org Current Opinion in Rheumatology: January 2016 - Volume 28 - Issue 1 - p 45-50 doi: 10.1097/BOR.0000000000000231 Buy Metrics Abstract Purpose of review Current trends in the management of Behçet's syndrome will be reviewed in this article. Recent findings Biologic agents have gained increasing importance over the years in the management of Behçet's syndrome. Long-term results of observational studies have shown that anti-tumor necrosis factor agents may be effective in Behçet's syndrome patients with refractory eye involvement. Case series reporting about use of anti-tumor necrosis factor agents in vascular and gastrointestinal involvement have also shown good results. Caution is required for infectious complications with these agents. Apremilast is an immunomodulatory agent that works through phosphodiesterase 4 inhibition. A randomized controlled trial has shown that it is effective for the management of oral and genital ulcers and is generally well tolerated. Summary The outcome of Behçet's syndrome with major organ involvement has improved with more effective management strategies, especially with the use of biologic agents in severe cases. Controlled trials are needed to guide physicians in making treatment decisions. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.